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Abstract 
Purpose: To investigate the in vitro pharmacokinetics of sirolimus-coated stent for tracheal stenosis  
Methods: Naked nickel titanium alloy stent was placed in methylene chloride leaching solution with 
different ratios of sirolimus/poly(lactic-co-glycolic acid) (PLGA). The morphology, thickness, and pellicles 
on the surface of the stent were observed by scanning electronic microscopy. Drug release from the 
stent was determined by enzyme amplification immunoassay. 
Results: Sirolimus was smoothly and uniformly attached to the stent, with an optimal sirolimus: PLGA 
coating ratio of 1:10. Further increases in sirolimus: PLGA ratio did not improve stent drug loading. A 
slow release of sirolimus from the stent was observed in the first week, followed by a rapid release and 
then much slower release process. Release of sirolimus persisted in the stent throughout the period of 
42 days. 
Conclusion: The sirolimus-coated stent has a good surface morphology, and sustained and effective 
drug release characteristics. Thus, it may be effective and safe for use in the treatment of tracheal 
stenosis in vivo. 
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Tracheal stenosis is a congenital or secondary 
disease caused by infection, cancer, trauma, or 
endometrial tuberculosis. Clinical manifestations 
of tracheal stenosis include cough, 
expectoration, dyspnea and respiratory failure. 
Stent implantation quickly relieves the dyspnea 
and improves the quality of patient’s life [1]. 
Under some conditions, stent (a small mesh tube 
that is used to treat narrow or weak arteries) 
placement is absolutely necessary, since surgery 
is contra-indicated [2]. Unfortunately, intra-
tracheal stent can damage the airway mucosa, 
and cause excessive proliferation of fibrous 
tissue. These lead to stent restenosis, which 
seriously affects the clinical efficacy of stent 
implantation [3]. In recent years, clinically-applied 
drug-eluting stent (DES) has been used in a wide 
range of patients with cardiopathy, 
gastroenteropathy or urologic diseases [4,5]. It 
has also been shown that DES significantly 
reduces incidence of stent restenosis when 
compared with bare-metal stent [6]. However 
research on applications of DES in tracheal 
stenosis treatment is still limited. 
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Sirolimus is a new immunosuppressant drug. 
Klugherz et al [7] found that sirolimus inhibits 
DNA synthesis in vascular smooth muscle cells 
and platelet-derived growth factor (PDGF)-
induced migration of cells, as well as proliferation 
and migration of smooth muscle cell and 
granuloma growth. Thus, sirolimus-coated stents 
have been widely used in the prevention of 
restenosis in patients with coronary heart 
disease needing coronary stent implantation [5]. 
However studies on the application of sirolimus-
eluting stent in intratracheal restenosis are 
limited. A drug-coated stent consists of bare-
metal stent, drugs, and a carrier. PLGA is a 
degradable, organic functional polymer approved 
by the US Food and Drug Administration (FDA). 
It can be used in the manufacture of medical 
devices, and has been applied in rat or rabbit 
model research on biological coating materials 
[8,9]. Sirolimus is a novel anti-tumor and 
immunosuppressive agent, which can suppress 
the growth of granuloma by inhibiting local 
inflammatory cascade [7,8,10,11]. Charytan et al 
[12-9] confirmed that m-TOR inhibitor sirolimus-
coated stent was better than bare-metal stent in 
the inhibition of coronary stent restenosis. 
However, the effects of sirolimus-coated stent or 
bare-metal stent on tracheal restenosis are still 
unknown. 
 
In this present study, we investigated the 
preparation of sirolimus-coated trachea stent and 
its pharmacokinetics in vitro. The duration of drug 
release, drug loading, optimum concentration 
ratio of drug and PLGA were determined, with a 
view to determining efficacy and safety of 
sirolimus-coated stent in the treatment of 




Preparation of sirolimus-coated trachea 
stents   
 
Bare nitinol stent was soaked in dichloromethane 
(Tianjin Tianli Chemicals Ltd) for 2 h and then 
washed with distilled water before it was placed 
in ventilation cabinet for 2 h to remove residual 
water. The stent was further washed with distilled 
water in ultrasonic cleaner for 20 min to remove 
surface impurities, and dried in the oven at r 50o. 
Sirolimus (Dalian Meilun Biotechnology Co., Ltd, 
Dalian, Liaoning, China) and PLGA (molecular 
weight: 1000, LA/GA 75:25, final concentration 2 
%) were dissolved in 20 mL dichloromethane in 
different ratios of 1:5, 1:10, 1:20, 1:30 or 1:40. 
The washed nitinol stent was then soaked in the 
above drug solutions for 2 h and was incubated 
in an oven at 37 oC 2 h. This procedure was 
repeated twice. 
 
Scanning electronic microscopy (SEM) of 
coated stent  
 
The morphology, thickness and drug pellicles of 
the prepared stent surface were observed with 
SEM (× 100). The coated stent was then put in 
phosphate buffered saline for 42 days, and 
changes in morphology and structure of the stent 
surface were observed with SEM. 
 
Evaluation of pharmacokinetics of DES in 
vitro  
 
The prepared stents were separately placed in 
glass tubes; 10 mL phosphate buffer (0.15mol/L, 
pH 7.4) were added as dissolution medium and 
all tubes were incubated at 37 oC in a shaker box 
stirred at 75 rev/min continuously for 48 h. The 
dissolution medium was then collected for 
determination of drug concentration, and was 
replaced with fresh phosphate buffer. This 
process was repeated consecutively for six 
weeks. Finally, the stent was put in 10 mL 
dichloromethane solution overnight at room 
temperature. The dichloromethane was then 
transferred into a vial to analyze its drug residue 
content.  Concentrations of sirolimus in 
dissolution medium were determined every two 
days by enzyme amplification immunoassay for a 
consecutive period of 42 days [13]. Drug release, 
cumulative release and residual amount of drugs 
in DES were determined. Total drug loading and 
drug release time from DES were calculated and 
the pharmacokinetic profiles of stent and optimal 





Data were analysis using descriptive statistics 
(percentages, mean ± standard deviation) as 
appropriate and one-way analysis of variance 
(ANOVA) was used for data comparison. P < 




Morphological characteristics of drug-eluting 
stents 
 
As shown in Figure 1a, drug pellicles were 
smoothly attached to the stent after the drug-
coated stent preparation procedures. After 
soaking in phosphate buffer for 42 days, the 
coated structure of stent surface changed with 
the degradation of PLGA, as was evident from 
the numerous holes on its surface (Figure 1b). 
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      Figure 1: Morphological characteristics of drug-eluting stents of sirolimus 
 
Optimal coating ratio of sirolimus and PLGA 
 
Drug-coated stents prepared at different 
sirolimus/PLGA ratios presented different drug 
loading profiles (Table 1). Maximum drug loading 
of stent was obtained at sirolimus/PLGA ratio of 
1:10. Stent drug loading did not increase with 
further increases in sirolimus/PLGA ratios. 
 
In vitro pharmacokinetics of sirolimus release  
 
The release profiles of sirolimus in DES over 
time are shown in Figure 2. From Figure 2, it can 
be seen that about 02-0.5 mcg of the drug was 
released in the first 5 days (in which case there 
was slow release of drug during that period) and 
rapid release occurred about the 5th – 9th day 
(during which about 60 %) of the drug was 
released) and thereafter a slower sustained 
release occurred. 
 
About 50 % stent-carried drug was released in 
first two weeks; there was nearly 70 % drug 
release in 28 days; while about 80 % was 
released in 42 days (Figure 3). 
 
 
Table 1: Drug loading and release at different drug-eluting stent ratios 
 
Drug-eluting stent Sirolimus/PLGA ratio 
1:5 1:10 1:20 1:30 1:40 
Sirolimus:PLGA 0.08g: 0.4g 0.04g: 0.4g 0.02g: 0.4g 0.0013g: 0.4g 0.01g: 0.4g 
Drug release (µg) 39.98 80.07 69.98 32.93 27.52 
 
 
             Figure 2: In vitro dailyrelease of sirolimus from sirolimus-coated stent  
.  
A B 
Wang et al 




































In this study, a sustained and effective role of 
sirolimus-coated stent on drug release has been 
found. Zhu et al [14] demonstrated for the first 
time that drug-eluting stent prepared from 
mitomycin C-coated tracheal stent is an effective 
and most promising treatment for stent 
restenosis. The drugs in coated stent can be 
released directly and continuously to a specific 
site without interacting with other tissues. This 
reduces incidence of restenosis. In this study, we 
developed the sirolimus-coated stent with 
favorable surface morphology and good drug 
release, which was evaluated as safe, effective 
in the treatment of tracheal stenosis in vivo. It 
has been demonstrated that the performance of 
DES depends on drug loading, drug release rate 
and duration. Drug/coating ratio plays an 
important role in this process [15]. The results of 
our study suggest that the best ratio for sirolimus 
: PLGA coating is 1:10, which enables the stent 
carry the highest amount of drug. Drug loading 
did not increase with increase the concentration 
of sirolimus in solution, suggesting a saturation 
effect. Kong et al [16] reported that the optimal 
paclitaxel : stent coating ratio was 1:20, while 
Yin-Kai Chao et al [17] determined that the 
optimal cisplatin : coating ratio was 1:9. These 
differences may be related to differences in 
solubilities of drugs. 
 
Soaking is a relatively simple and important 
method for preparing coated stents [18]. Drug 
pellicles were attached to the newly prepared 
stent uniformly and smoothly. However, after 
soaking in phosphate buffer for 42 days, many 
holes were observed in the surface of drug-
coated stent with the degradation of PLGA, 
indicating that sirolimus might diffuse through 
these gaps or holes. 
 
The drug release curve of drug-coated stents is 
uncertain [19]. In sirolimus-eluting stents, drug 
release lasted for more than 42 days while about 
50 % stent carried drugs was released in first two 
weeks. Although different drug : coating ratios 
had different drug concentrations, the processes 
of drug release were roughly the same in vitro. 
Therefore, suitable coating materials and 
appropriate drug : coating ratios are key factors 
for maximizing the effects of DES. 
 
Previous studies suggested that the mechanisms 
of in vitro drug release in DES were mainly 
based on drug diffusion and degradation of the 
stent polymer [20,21]. Pires et al [22] found that 
there was a quick release period and a 
subsequent slow release period of drugs from 
DES in vitro. As shown in present study, the 
sirolimus dissolved rapidly and the stent polymer 
was eroded in the quick release period. 
Thereafter, the drug release profile entered a 
slow phase until the end based on gradual 
diffusion through porous regions when the 
polymer materials were degraded or flaked.  
 
The profiles of prepared DES need to be further 
confirmed in vivo, even though some researchers 
have suggested that sirolimus metabolism in vitro 
is similar to that in vivo [23] Drug release process 
in vitro may be actually different from that in vivo 
due to changes in environment and acid-base 




We have successfully produced a trachea 
sirolimus-coated stents and evaluated their drug 
release pharmacokinetics in vitro. The results 
show that the DES has a good surface 
morphology, as well as sustained and effective 
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